Suboxone MDL Case Count History: Growth, Screening, and a Recent Plateau

From 677 pending actions to more than 1,800

The first snapshot in this comparison is July 1, 2024, five months after MDL 3092 was created. JPML listed 677 actions pending and 678 historical actions. On January 2, 2025, it listed 754 pending and 762 historical. That represents a net increase of 77 pending and 84 historical actions during the six-month interval, while the gap between the columns grew from one to eight.

The docket expanded much more sharply afterward. On April 1, 2026, JPML reported 1,836 pending and 1,907 historical actions. On July 1, 2026, it reported 1,832 pending and 1,908 historical. The last quarter therefore produced a net pending decline of four and a historical increase of one. Those exact figures show a plateau at the reporting dates, not every filing and departure that occurred between them.

Pending and historical answer different questions

Pending is the active federal MDL inventory on the report date. Historical is the cumulative total of actions that have entered the MDL. In July 2026, the 76-action difference means 76 actions in the docket’s history were not then pending. It does not tell readers whether those actions were dismissed with prejudice, dismissed without prejudice, transferred, consolidated, resolved, or otherwise changed status.

That distinction is especially important in Suboxone because the court has enforced census and record-production requirements. Some plaintiffs who failed to comply with orders faced dismissal, while others showed good cause and continued. A net monthly change compresses all such activity with any new filings and other docket events. It cannot be translated into a settlement rate or a count of deficient claims.

What drove the structured review of filed cases

Case Management Order 12 established a census for cases filed on or before October 7, 2024, seeking information and initial proof of Suboxone film use and dental injury. Case Management Order 15 then created a Record Collection Pool for the first stage of bellwether selection. The court later issued deficiency and show-cause procedures when required information was missing.

These steps are designed to make a large docket administrable and to develop selected cases on real records. They do not establish that every filing has equivalent evidence, that every dental condition was caused by Suboxone film, or that every plaintiff belongs in a future settlement. The count includes actions at different procedural stages and with different product, prescription, dental, timing, and alternative-cause evidence.

Why the 2026 plateau is not a settlement signal

The difference between 1,836 pending actions in April and 1,832 in July is too small to support a story beyond the net figures. One cannot infer that filings stopped, four cases settled, or the parties reached a global agreement. Multiple arrivals and departures could yield the same endpoint. The official court page lists continued bellwether, records, common-benefit, and leadership orders rather than a universal settlement announcement.

Nor does a plateau predict when trials or resolutions will occur. Bellwether timing depends on records, discovery, expert work, motion practice, and later scheduling orders. A reported date can change. Settlement negotiations, if any, may be confidential. Without a public agreement or order, websites should not invent payout ranges, eligibility criteria, enrollment deadlines, or claims that the docket is “about to settle.”

What the count leaves out of an individual dental claim

MDL 3092 concerns allegations involving brand-name Suboxone buprenorphine/naloxone film. FDA’s 2022 warning is broader, covering buprenorphine medicines dissolved in the mouth. A person’s records therefore must identify the product and formulation rather than relying on “buprenorphine” as a generic label. Pharmacy history, prescribing notes, dental charts and X-rays, treatment, baseline disease, dry mouth, tobacco, diet, and other medicines can all matter.

The July 2026 count confirms a substantial active federal proceeding, nothing more. It does not prove that Suboxone film caused one person’s decay, that a warning claim is timely under a particular state’s law, or that treatment costs will be reimbursed. Patients should not change opioid-use-disorder treatment based on litigation numbers; FDA advises discussing decisions with healthcare professionals and maintaining preventive dental care.

Reader questions

Frequently asked questions